title: Cyclic AMP efflux is regulated by occupancy of the adenosine receptor in pig aortic smooth muscle cells.
abstract: Cultured pig aortic smooth muscle cells respond to extracellular adenosine by activating adenylate cyclase and by initiating the efflux of cAMP. In the presence of extracellular adenosine, efflux is first order with respect to intracellular cAMP concentration up to at least 125 pmol/10(6) cells. The apparent first-order rate constant for the efflux of cAMP increases in a dose-dependent manner in response to extracellular adenosine or 5-N-ethylcarboxamide adenosine. The EC50 for adenosine for promoting cAMP efflux is 12 microM. For cells stimulated with 5-N-ethylcarboxamide adenosine, the EC50 is 5 microM. When extracellular adenosine is removed, efflux stops abruptly. Cellular cAMP content falls but is still in a range that supports cAMP efflux when agonist is present. Efflux is not affected by H8 (N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride), an inhibitor of cAMP-dependent protein kinase. These data suggest that in pig aortic smooth muscle cells, the efficiency of cAMP efflux is regulated by A2 receptor occupancy.
authors.affiliation: Department of Biochemistry, University of Massachusetts, Amherst 01003.
authors.forename: T F
authors.initials: TF
authors.lastname: Fehr
authors.forename: E S
authors.initials: ES
authors.lastname: Dickinson
authors.forename: S J
authors.initials: SJ
authors.lastname: Goldman
authors.forename: L L
authors.initials: LL
authors.lastname: Slakey
mesh_terms: D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000494:pharmacology; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D019830:Adenosine-5'-(N-ethylcarboxamide); D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D001011:Aorta; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D007546:Isoquinolines / Q000494:pharmacology; D007700:Kinetics; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism*; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases / Q000378:metabolism; D011983:Receptors, Purinergic / Q000378:metabolism*; D013552:Swine; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D007546:Isoquinolines; D047428:Protein Kinase Inhibitors; D011983:Receptors, Purinergic; D014665:Vasodilator Agents; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D019830:Adenosine-5'-(N-ethylcarboxamide); C053177:N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide; D000242:Cyclic AMP; D011494:Protein Kinases; D000262:Adenylyl Cyclases; D000241:Adenosine